Michael Porter, Ph.D., has joined the board of directors of ExThera Medical Corporation, a privately held medical technology company focused on the therapeutic reduction of drug-resistant pathogens and sepsis mediators in whole blood. ExThera’s Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) has a CE Mark in Europe for the treatment of a wide range of bloodstream infections. In the USA Seraph 100 has Emergency Use Authorization from FDA, where it is being used successfully in the treatment of COVID-19 patients, many of whom are critically ill.
Professor Porter, the Bishop William Lawrence University Professor at Harvard Business School, is recognized as a leading authority on competitive strategy, the competitiveness and economic development of nations and regions, and the application of competition and strategy principles to address social problems such as health care, the environment, and creating economic opportunity by increasing corporate social impact. Harvard University and Harvard Business School jointly created the Institute for Strategy and Competitiveness dedicated to furthering Professor Porter’s research. In addition, he has founded several non-profit organizations including the Initiative for a Competitive Inner City (ICIC), focused on revitalizing distressed economic urban communities, and the International Consortium for Health Outcome Measurements (ICHOM), the leader in developing patient centered health outcomes by medical condition, today encompassing 33 conditions affecting a substantial part of the disease burden.
“Dr. Porter’s global expertise in the strategic development of commercial organizations, his work on transformation of healthcare, and his relationships with numerous health systems and delivery organizations, will provide a new and welcomed perspective to ExThera as we expand the markets for our novel blood filter,” said Bob Ward NAE President and Chairman of the Board. “Michael will provide world class guidance as a strategic advisor to the Company. We are excited to welcome him to the Board as we begin a period of significant growth.”
Professor Porter holds a Bachelor’s degree in aerospace engineering from Princeton University where he was elected to Phi Beta Kappa, a Master’s degree in Business Administration with high distinction from Harvard Business School where he was a George F. Baker Scholar, and a Ph.D. in Business Economics from Harvard University. He has also been awarded numerous honorary doctorates from universities around the world. He is a member of the Princeton University Board of Trustees, and the author of 20 books and over 150 articles. Professor Porter also co-chairs the editorial board for New England Journal of Medicine Catalyst, a leading journal for new approaches to health care delivery.
Professor Porter commented on joining the ExThera board, “I am truly excited about ExThera Medical’s business potential, and I am honored to be affiliated with this life saving company at a time when medical innovation is more important than ever. ExThera Medical is a leading innovator in health technology and treating some of the most challenging and life-threatening medical conditions of our time.”